Study Evaluating the Impact of Using Triplex Rapid Diagnostic Tests (SARS-CoV-2/Influenza/RSV) on Antibiotic Prescribing

Recruiting N/A Interventional Study
Respiratory Infections Antibiotic
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
1 and older
Sex
Any
Study type
Interventional
Purpose
Health Services Research
Participants needed
2,000 (estimated)
Sponsor
Assistance Publique - Hôpitaux de Paris · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Respiratory infections are very common, especially during winter, and are often caused by viruses such as influenza, SARS-CoV-2 or respiratory syncytial virus (RSV). These illnesses are generally mild, but their symptoms do not always allow a clear distinction to be made between a viral infection and a bacterial infection. In the absence of a precise diagnosis, antibiotics may be prescribed when …
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Age ≥ 1 year 2. Presenting with: * Either fever (temperature \> 38°C measured by patient or physician) within the past 72 hours, and one of the following symptom combinations: 1. Rhinorrhea (white, yellow, or green discharge) and/or nasal obstruction, and cough …
Contacts

Aurélien DINH, MD, PhD

+33 1 47 10 77 60

aurelien.dinh@aphp.fr

CONTACT

Jacques ROPERS, PharmD

+33 1 42 16 03 48

jacques.ropers@aphp.fr

CONTACT